166 related articles for article (PubMed ID: 18182480)
1. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026.
Moncunill G; Armand-Ugón M; Clotet-Codina I; Pauls E; Ballana E; Llano A; Romagnoli B; Vrijbloed JW; Gombert FO; Clotet B; De Marco S; Esté JA
Mol Pharmacol; 2008 Apr; 73(4):1264-73. PubMed ID: 18182480
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4.
Schols D; Struyf S; Van Damme J; Esté JA; Henson G; De Clercq E
J Exp Med; 1997 Oct; 186(8):1383-8. PubMed ID: 9334378
[TBL] [Abstract][Full Text] [Related]
4. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
5. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
6. CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.
Klasse PJ; Rosenkilde MM; Signoret N; Pelchen-Matthews A; Schwartz TW; Marsh M
J Virol; 1999 Sep; 73(9):7453-66. PubMed ID: 10438835
[TBL] [Abstract][Full Text] [Related]
7. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.
Schols D; Esté JA; Henson G; De Clercq E
Antiviral Res; 1997 Aug; 35(3):147-56. PubMed ID: 9298754
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles.
DeMarco SJ; Henze H; Lederer A; Moehle K; Mukherjee R; Romagnoli B; Robinson JA; Brianza F; Gombert FO; Lociuro S; Ludin C; Vrijbloed JW; Zumbrunn J; Obrecht JP; Obrecht D; Brondani V; Hamy F; Klimkait T
Bioorg Med Chem; 2006 Dec; 14(24):8396-404. PubMed ID: 17010618
[TBL] [Abstract][Full Text] [Related]
9. Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection.
Cabrera C; Gutiérrez A; Blanco J; Barretina J; Litovchick A; Lapidot A; Evdokimov AG; Clotet B; Esté JA
AIDS Res Hum Retroviruses; 2000 May; 16(7):627-34. PubMed ID: 10791873
[TBL] [Abstract][Full Text] [Related]
10. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.
Hatse S; Bridger G; de Clercq E; Schols D
Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL443-52. PubMed ID: 14995074
[TBL] [Abstract][Full Text] [Related]
11. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
[TBL] [Abstract][Full Text] [Related]
12. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship of neomycin, paromomycin, and neamine-arginine conjugates, targeting HIV-1 gp120-CXCR4 binding step.
Borkow G; Vijayabaskar V; Lara HH; Kalinkovich A; Lapidot A
Antiviral Res; 2003 Nov; 60(3):181-92. PubMed ID: 14638394
[TBL] [Abstract][Full Text] [Related]
14. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.
Schols D; Esté JA; Cabrera C; De Clercq E
J Virol; 1998 May; 72(5):4032-7. PubMed ID: 9557691
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.
Bridger GJ; Skerlj RT; Padmanabhan S; Martellucci SA; Henson GW; Struyf S; Witvrouw M; Schols D; De Clercq E
J Med Chem; 1999 Sep; 42(19):3971-81. PubMed ID: 10508445
[TBL] [Abstract][Full Text] [Related]
16. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.
Daelemans D; Schols D; Witvrouw M; Pannecouque C; Hatse S; van Dooren S; Hamy F; Klimkait T; de Clercq E; VanDamme AM
Mol Pharmacol; 2000 Jan; 57(1):116-24. PubMed ID: 10617686
[TBL] [Abstract][Full Text] [Related]
17. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
18. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
Murakami T; Kumakura S; Yamazaki T; Tanaka R; Hamatake M; Okuma K; Huang W; Toma J; Komano J; Yanaka M; Tanaka Y; Yamamoto N
Antimicrob Agents Chemother; 2009 Jul; 53(7):2940-8. PubMed ID: 19451305
[TBL] [Abstract][Full Text] [Related]
19. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
20. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
Hatse S; Princen K; Gerlach LO; Bridger G; Henson G; De Clercq E; Schwartz TW; Schols D
Mol Pharmacol; 2001 Jul; 60(1):164-73. PubMed ID: 11408611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]